All In Biotech

Drug Trial Radar · NCT01902290

Study of Efficacy and Safety of Brodalumab Compared With Placebo in Adults With Inadequately Controlled Asthma With High Bronchodilator Reversibility

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Brodalumab in Subjects With Inadequately Controlled Asthma and High Bronchodilator Reversibility

Last checked: Nov 20, 2026Latest source record: Sep 21, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 421 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

421

Actual

Start

May 22, 2013

Primary completion

May 15, 2015

Study completion May 15, 2015

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
Collaborators
Kyowa Kirin Co., Ltd.; AstraZeneca
First posted
Jul 18, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if brodalumab (AMG 827) is safe and effective compared to placebo as measured by change in Asthma Control Questionnaire (ACQ) composite scores.

Conditions

  • Asthma

Interventions

  • PlaceboBiological

    Placebo administered subcutaneously

  • BrodalumabBiological

    Brodalumab administered subcutaneously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Asthma Control Questionnaire (ACQ) Composite Score at Week 24Time frame: Baseline and week 24

Locations

161 sites in 15 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Glendale, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Scottsdale, Arizona

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Bakersfield, California

  • Research Site

    Encinitas, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Newport Beach, California

  • Research Site

    North Hollywood, California

  • Research Site

    Orange, California

  • Research Site

    Palmdale, California

  • Research Site

    Rolling Hills Estates, California

  • Research Site

    San Diego, California

  • Research Site

    San Diego, California

  • Research Site

    San Jose, California

  • Research Site

    Santa Monica, California

  • Research Site

    Stockton, California

  • Research Site

    Colorado Springs, Colorado

  • Research Site

    Waterbury, Connecticut

  • Research Site

    Aventura, Florida

  • Research Site

    Hialeah, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Lynn Haven, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Port Orange, Florida

  • Research Site

    Tallahassee, Florida

  • Research Site

    Decatur, Georgia

  • Research Site

    Lawrenceville, Georgia

  • Research Site

    Eagle, Idaho

  • Research Site

    Chicago, Illinois

  • Research Site

    Chicago, Illinois

  • Research Site

    Normal, Illinois

  • Research Site

    Peoria, Illinois

  • Research Site

    Iowa City, Iowa

  • Research Site

    Paducah, Kentucky

  • Research Site

    Baltimore, Maryland

  • Research Site

    Baltimore, Maryland

Showing 40 of 161 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.